

## AVATROMBOPAG tablets (Doptelet® ▼) for primary chronic immune thrombocytopenia (ITP)

**The Cheshire and Merseyside Interim Area Prescribing Group recommends the prescribing of AVATROMBOPAG tablets (Doptelet® ▼), by specialists only, for primary chronic immune thrombocytopenia (ITP) in accordance with NICE TA853.**

**RED**

[NICE technology appraisal \(TA\) 853](#) (15 December 2022) recommends avatrombopag, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids and immunoglobulins) in adults, only if the company provides it according to the commercial arrangement.<sup>[1]</sup>

Prescribing and monitoring of therapy must be retained by a specialist in the management of chronic ITP.

### Costing information

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because avatrombopag is a further treatment option for patients alongside other thrombopoietin receptor agonists and the overall cost of treatment for this patient group will be similar.<sup>[2]</sup>

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 853; [Avatrombopag for treating primary chronic immune thrombocytopenia](#), 15 December 2022. Accessed online 03 January 2023.
2. National Institute for Health and Care Excellence. Technology Appraisal 853; [Resource impact statement: Avatrombopag for treating primary chronic immune thrombocytopenia](#), 15 December 2022. Accessed online 03 January 2023.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.